immatics biotechnologies GmbH-Product Pipeline Review-2015

immatics biotechnologies GmbH-Product Pipeline Review-2015

  • Products Id :- GMDHC06798CDB
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

immatics biotechnologies GmbH-Product Pipeline Review-2015


Global Markets Direct's, 'immatics biotechnologies GmbH-Product Pipeline Review-2015', provides an overview of the immatics biotechnologies GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of immatics biotechnologies GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of immatics biotechnologies GmbH including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of immatics biotechnologies GmbH's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the immatics biotechnologies GmbH's pipeline products

Reasons To Buy

Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus

Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of immatics biotechnologies GmbH and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of immatics biotechnologies GmbH

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

immatics biotechnologies GmbH Snapshot 4

immatics biotechnologies GmbH Overview 4

Key Information 4

Key Facts 4

immatics biotechnologies GmbH-Research and Development Overview 5

Key Therapeutic Areas 5

immatics biotechnologies GmbH-Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products-Monotherapy 8

Pipeline Products-Out-Licensed Products 9

Out-Licensed Products/Combination Treatment Modalities 10

immatics biotechnologies GmbH-Pipeline Products Glance 11

immatics biotechnologies GmbH-Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

immatics biotechnologies GmbH-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

immatics biotechnologies GmbH-Drug Profiles 14

IMA-901 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

IMA-910 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

APVAC-1 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

APVAC-2 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

IMA-950 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

immatics biotechnologies GmbH-Pipeline Analysis 24

immatics biotechnologies GmbH-Pipeline Products by Target 24

immatics biotechnologies GmbH-Pipeline Products by Route of Administration 25

immatics biotechnologies GmbH-Pipeline Products by Molecule Type 26

immatics biotechnologies GmbH-Recent Pipeline Updates 27

immatics biotechnologies GmbH-Company Statement 30

immatics biotechnologies GmbH-Locations And Subsidiaries 31

Head Office 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

immatics biotechnologies GmbH, Key Information 4

immatics biotechnologies GmbH, Key Facts 4

immatics biotechnologies GmbH-Pipeline by Indication, 2015 6

immatics biotechnologies GmbH-Pipeline by Stage of Development, 2015 7

immatics biotechnologies GmbH-Monotherapy Products in Pipeline, 2015 8

immatics biotechnologies GmbH-Out-Licensed Products in Pipeline, 2015 9

immatics biotechnologies GmbH-Out-Licensed Products/ Combination Treatment Modalities, 2015 10

immatics biotechnologies GmbH-Phase III, 2015 11

immatics biotechnologies GmbH-Phase II, 2015 12

immatics biotechnologies GmbH-Phase I, 2015 13

immatics biotechnologies GmbH-Pipeline by Target, 2015 24

immatics biotechnologies GmbH-Pipeline by Route of Administration, 2015 25

immatics biotechnologies GmbH-Pipeline by Molecule Type, 2015 26

immatics biotechnologies GmbH-Recent Pipeline Updates, 2015 27

List of Figures

immatics biotechnologies GmbH-Pipeline by Top 10 Indication, 2015 6

immatics biotechnologies GmbH-Pipeline by Stage of Development, 2015 7

immatics biotechnologies GmbH-Monotherapy Products in Pipeline, 2015 8

immatics biotechnologies GmbH-Pipeline by Top 10 Route of Administration, 2015 25

immatics biotechnologies GmbH-Pipeline by Top 10 Molecule Type, 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of immatics biotechnologies GmbH; immatics biotechnologies GmbH - Key Therapeutics; immatics biotechnologies GmbH - Pipeline Overview and Promising Molecules; immatics biotechnologies GmbH - News; immatics biotechnologies GmbH - Latest Updates; immatics biotechnologies GmbH - Pipeline; immatics biotechnologies GmbH - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]